A Phase II Study of 9MW3811 in Patients With Pathological Scar

Exclusion Criteria

• •Contracture scar causing deformity
• •All eligible scars either \>10 cm in length and \>5 cm in width, or located exclusively on sun-exposed areas (head, face, hands)
• •Evidence of scar infection or active systemic infection requiring treatment
• •Use of anti-scar medications (e.g., corticosteroids, immunosuppressants) or anti-scar procedures (surgery, laser, radiation, etc.) within 4 weeks prior to first dose
• •Prior treatment with IL-11 cytokine or IL-6 family targeted therapy (e.g., tocilizumab) within specified washout periods
• •Participation in another interventional study within 28 days
• •Positive serology for HBV, HCV, HIV, or syphilis with clinical significance
• •History of severe allergy or known hypersensitivity to study drug components
• •Clinically significant laboratory abnormalities (eGFR \<90 mL/min/1.73m², PLT \<100×10⁹/L, QTc \>450/470 ms, bilirubin \>1.5×ULN, AST/ALT \>1.5×ULN)
• •Alcohol or drug abuse within 1 year
• •Pregnancy, breastfeeding, or unwillingness to use contraception
• •Any other condition that, in the investigator's judgment, would compromise subject safety or study compliance